Fredun Pharmaceuticals Ltd (FREDUN) — concall transcript | 31 March 2026

· BSE 🟡 Notable ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Fredun Pharmaceuticals reported strong FY26 revenue growth and outlined strategic expansion in new-age segments including pet care and mobility.
🔄 What Changed
Revenue grew 40.08% YoY to INR639.12 crores, with new-age businesses contributing INR 42-43 crores in FY26 and targeting 50-70% of revenue within 2-3 years.
🔮 What's Next
Targeting 25-30% revenue growth in FY27 and 10-12% PAT margins within the next few years, with new-age businesses expected to contribute 50-70% of revenue.
💡 Investor Takeaway
The company is transitioning to a high-margin, diversified model with strong growth in pet care and mobility, supported by scalable manufacturing and direct-to-consumer channels.

Fredun Pharmaceuticals reported 27.27% YoY revenue growth to INR213 crores in Q4 FY26 and 40.08% YoY growth to INR639.12 crores for FY26, driven by hormonal, anti-aging, mobility, and pet care segments. Management highlighted plans to launch medicated hormone products via doctor channels and online platforms, exclusive NAD+ API imports, and expansion of pet care with 42 functional food variants and diagnostics. The company targets 25-30% revenue growth in FY27, 10-12% PAT margins, and aims for 50-70% contribution from new-age businesses within 2-3 years. It plans to add 12-13 packing lines by September and expand manufacturing capacity, supported by strong order backlogs and improved cash flow.

📄 View Original Announcement (PDF)

About Fredun Pharmaceuticals Ltd (FREDUN)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹2,020.29 Cr P/E: 14.3 ROE: 16.6% ROCE: 20.5% Div Yield: 0.06%

View full FREDUN stock details →

📡 Get AI alerts when FREDUN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track FREDUN — Free

📊 More FREDUN filings

See all FREDUN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when FREDUN files new disclosures

Track FREDUN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FREDUN — Free

Free account · 2 AI queries/day